by Ilaria Colombo | 19 July 2024 | Women's Cancers
Compared to other tumor types, the development of HER2-targeted therapies for gynecological malignancies is lagging somewhat behind. Nevertheless, promising data have already been generated in the treatment of endometrial, cervical, and ovarian cancer.  © Freepik |...
by Deborah Mukherji | 3 July 2024 | Urogenital
Clinical trials investigating various drugs in patients with metastatic hormone-sensitive or castration-resistant prostate cancer have revealed significant benefits. While research is ongoing to shed light on issues such as sequencing, treatment de-escalation and...
by Alison Birtle | 5 June 2024 | Urogenital
Enfortumab vedotin (EV) plus pembrolizumab has recently been established as the new first-line treatment standard in advanced urothelial carcinoma. Clear guidance on how to manage the typical side effects of this regimen is necessary to allow for the successful use of...